MetaVia

Key facts

Headquarters

Cambridge, Massachusetts, United States

Employees

13

Industries

Biotechnology, Healthcare

Status

Public (MTVA)

Website

metaviatx.com

LinkedIn

Company page

Recent activity at MetaVia

• Nov 05, 2026: SEC 8-K (8.01): On November 5, 2026, Metavia Inc. posted an updated corporate presentation to its website, which may be utilized for various investor communications and conferences. This presentation is referenced in connection with ongoing corporate strategies and investor relations. The company emphasizes that the information on its website is not part of the filing, serving merely as inactive references. The filing includes forward-looking statements regarding the company's performance, indicating that actual future results may differ significantly from current expectations. The presentation is attached as Exhibit 99.2 to the 8-K report.
• Oct 28, 2026: SEC 8-K (7.01): On October 28, 2026, MetaVia Inc. announced via a press release that their abstract highlighting data from the Phase 1 clinical trial of DA-1726 has been accepted for an oral presentation at the Precision Liver Symposium 2026, scheduled for November 4, 2026, in Denver, Colorado. This dual oxyntomodulin (OXM) analog targets both GLP-1 (GLP1R) and glucagon (GCGR) receptors, indicating potential advancements in treatments for metabolic diseases. The press release, attached as Exhibit 99.1, emphasizes the significance of this development for the company and the medical community, although it clarifies that the information shared is furnished and not filed under the Exchange Act. This announcement is timely and relevant for investors and stakeholders tracking the company's clinical progress.
• Oct 13, 2026: MetaVia Inc. Appoints Sarah Browne, M.D. as Chief Medical Officer
• Oct 13, 2026: SEC 8-K (8.01): On October 12, 2026, Metavia Inc. appointed Sarah Kaplan Browne, M.D. to the position of Chief Medical Officer, marking a significant change in the company's management team. This transition is expected to enhance the company's strategic direction in medical leadership and development. The appointment reflects the company's commitment to advancing its clinical initiatives and improving its healthcare offerings. The announcement of this appointment was further detailed in a press release dated October 13, 2026.
• Sep 09, 2026: SEC 8-K (7.01): On September 9, 2026, MetaVia Inc. announced results from a preclinical tissue distribution study for its compound DA-1726. The study revealed that the radioactivity from DA-1726 is slowly absorbed and extensively distributed throughout the body following subcutaneous administration. Notably, the highest tissue exposure was observed in adipose (fat) tissue, which could have significant implications for the compound's therapeutic applications. This announcement reflects the company's ongoing research efforts and strategic focus on the development of DA-1726, suggesting potential advancements in treatment methodologies.
• Aug 06, 2026: SEC 8-K (7.01): On August 6, 2026, Metavia Inc. posted an updated corporate presentation on its website, which may be used for investor communications and presentations. This filing serves to inform stakeholders of the availability of this presentation and indicates the company's ongoing engagement with its investor base. The updates included in the presentation and related press release reflect current expectations and may contain forward-looking statements about future performance, which are subject to various risks. The filing suggests a proactive approach to transparency under Regulation FD, providing stakeholders with valuable insights into the company's strategic outlook.
• Jul 09, 2026: SEC 8-K (8.01): On July 9, 2026, MetaVia Inc. provided an update on its ongoing Part 3 of its Phase 1 clinical trial for the investigational drug DA-1726, aimed at treating obesity. All currently enrolled active patients have successfully completed the dose titration phase and are now receiving their target doses of 48 mg and 64 mg across both study cohorts. The company plans to release data from this trial in the fourth quarter of 2026, indicating a strategic movement towards bringing this potential treatment closer to market. This update is significant for stakeholders as it outlines the progress of a clinical trial that could impact future business operations and market position.
• Jul 02, 2026: SEC 8-K (8.01):
• Jun 08, 2026: SEC 8-K (8.01): On June 8, 2026, the Company presented late-breaking data at the ADA 2026 Scientific Sessions highlighting its obesity and metabolic disease portfolio. The presentation included interim results from a Phase 1 study of DA-1726, showing significant weight reductions in obese adults, with a 6.1% decrease at Day 26 and 9.1% at Day 54, alongside improvements in waist circumference and BMI. Preclinical studies of vanoglipel in combination with resmetirom and metformin demonstrated promising weight-loss effects and metabolic improvements in diet-induced obese mouse models. These results may support further development of these treatments for obesity and related metabolic disorders.
• Jun 08, 2026: SEC 8-K (5.02): On June 8, 2026, at the virtual annual meeting of stockholders, MetaVia Inc. announced the approval of the first amendment to the 2022 Amended and Restated Equity Incentive Plan. This amendment, which was effective immediately upon stockholder approval, increases the number of shares of common stock available for issuance under the plan by 200,000 shares. The amendment is part of broader governance changes discussed during the meeting alongside other corporate proposals, indicating a strategic move to enhance stockholder incentives through equity compensation. The details regarding this amendment are further outlined in the company's definitive proxy statement filed on April 27, 2026.

MetaVia funding history

Leadership

• Richard Kang, Executive Officer, Director
• Na Kim, Director
• Jason Groves, Director
• Hyung Kim, Director
• Michael Salsbury, Director
• Douglas Swirsky, Director
• Andrew Koven, Director
• Akash Bakshi, Executive Officer, Director
• Jeong Oh, Director

Verified email and direct lines for MetaVia’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

MetaVia in the news

• MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire (Aug 06, 2026)
• MetaVia Inc. (MTVA) Company Profile & Facts - Yahoo Finance - Yahoo! Finance Canada (Nov 30, 2024)
• MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PR Newswire (Jun 17, 2026)
• MetaVia Inc. (MTVA) Company Information - Simply Wall St (Nov 30, 2024)

Companies similar to MetaVia

• Ensysce Biosciences · Biotechnology, Healthcare
• UbiVac · Biotechnology, Healthcare
• Axial Therapeutics · Biotechnology, Healthcare
• Akadeum Life Sciences · Biotechnology, Healthcare
• Enveric Biosciences · Biotechnology, Healthcare

About MetaVia: questions and answers

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy